[go: up one dir, main page]

MX2020003001A - Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. - Google Patents

Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.

Info

Publication number
MX2020003001A
MX2020003001A MX2020003001A MX2020003001A MX2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A MX 2020003001 A MX2020003001 A MX 2020003001A
Authority
MX
Mexico
Prior art keywords
water
roflumilast
miscible
pharmaceutically acceptable
pharmaceutical compositions
Prior art date
Application number
MX2020003001A
Other languages
English (en)
Inventor
David W Osborne
Original Assignee
Arcutis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020003001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arcutis Inc filed Critical Arcutis Inc
Publication of MX2020003001A publication Critical patent/MX2020003001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La baja solubilidad acuosa de roflumilast en preparaciones parenterales y emulsiones tópicas, suspensiones, geles o soluciones se puede mejorar al incluir una mezcla de solventes miscibles en agua en la composición farmacéutica; la mezcla de solventes miscibles en agua puede incluir dietilen glicol monoetil éter (Nombre comercial Transcutol(r); abreviado DEGEE) y agua; la relación de dietilen glicol monoetil éter a agua es de 1:10 a 20:1; la composición resultante tiene biodisponibilidad y eficacia mejoradas y se puede utilizar para inhibir la fosfodiesterasa 4 en un paciente en necesidad de dicho tratamiento.
MX2020003001A 2017-09-22 2018-09-19 Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables. MX2020003001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/712,900 US11534493B2 (en) 2017-09-22 2017-09-22 Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
PCT/US2018/051691 WO2019060379A1 (en) 2017-09-22 2018-09-19 PHARMACEUTICAL COMPOSITIONS OF ROFLUMILAST IN AQUEOUS MIXTURES OF PHARMACEUTICALLY ACCEPTABLE SOLVENTS MISCIBLE TO WATER

Publications (1)

Publication Number Publication Date
MX2020003001A true MX2020003001A (es) 2020-09-28

Family

ID=63794682

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003001A MX2020003001A (es) 2017-09-22 2018-09-19 Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.
MX2023011557A MX2023011557A (es) 2017-09-22 2020-03-18 Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023011557A MX2023011557A (es) 2017-09-22 2020-03-18 Composiciones farmaceuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmaceuticamente aceptables.

Country Status (12)

Country Link
US (3) US11534493B2 (es)
EP (2) EP4316590A3 (es)
JP (3) JP7191944B2 (es)
KR (1) KR102681877B1 (es)
CN (2) CN119386013A (es)
AU (1) AU2018337752B2 (es)
CA (1) CA3076002A1 (es)
EA (1) EA202090813A1 (es)
ES (1) ES2972843T3 (es)
IL (1) IL273376B2 (es)
MX (2) MX2020003001A (es)
WO (1) WO2019060379A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US20210161870A1 (en) * 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US11534493B2 (en) * 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
AU2019281888B2 (en) 2018-06-04 2024-05-02 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time
EP4041211A4 (en) * 2019-10-11 2023-09-06 Zenvision Pharma LLP IMPROVED TOPICAL COMPOSITION OF COLCHICINE
BR112022015104A2 (pt) * 2020-01-31 2022-09-27 Arcutis Biotherapeutics Inc Método para melhorar a distribuição e estender a meia-vida plasmática de uma composição de roflumilaste e uso de uma composição
MX2023006602A (es) 2020-12-04 2023-08-07 Arcutis Biotherapeutics Inc Formulación tópica de roflumilast que tiene propiedades antimicoticas.
WO2022169615A1 (en) * 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
WO2023129215A1 (en) 2021-12-28 2023-07-06 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
KR20250057103A (ko) 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물
WO2025054483A1 (en) 2023-09-07 2025-03-13 Arcutis Biotherapeutics, Inc. Dosing regimens using topical roflumilast compositions
US20250090509A1 (en) * 2023-09-15 2025-03-20 Arcutis Biotherapeutics, Inc. Methods of reducing itch using topical roflumilast compositions
CN117462487A (zh) * 2023-11-29 2024-01-30 沈阳药科大学 一种罗氟司特油凝胶及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2259692A (en) * 1991-07-03 1993-02-11 Sano Corporation Composition and method for transdermal delivery of diclofenac
SI0706513T1 (en) 1993-07-02 2002-10-31 Altana Pharma Ag Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
GB9618974D0 (en) * 1996-09-11 1996-10-23 Glaxo Group Ltd Medicaments
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK2020243T3 (en) * 2002-05-28 2018-11-19 Astrazeneca Ab Pharmaceutical composition which can be applied topically
DE602004023921D1 (de) 2003-03-10 2009-12-17 Nycomed Gmbh Neues verfahren zur herstellung vonroflumilast
US20060204526A1 (en) * 2003-08-13 2006-09-14 Lathrop Robert W Emulsive composition containing Dapsone
EP1670433B1 (en) * 2003-10-10 2011-11-23 Antares Pharma IPL AG Transdermal pharmaceutical formulation for minimizing skin residues
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
JPWO2006041121A1 (ja) * 2004-10-13 2008-05-15 協和醗酵工業株式会社 慢性皮膚疾患の治療および／または予防剤
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
CN101541321A (zh) * 2006-09-06 2009-09-23 Isw集团公司 局部用组合物
US7893097B2 (en) * 2008-02-02 2011-02-22 Dow Pharmaceutical Sciences, Inc. Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
WO2012135619A2 (en) * 2011-03-31 2012-10-04 Neuronex, Inc. Intranasal benzodiazepine pharmaceutical compositions
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
PT2704703T (pt) * 2011-05-03 2019-10-25 Aponia Laboratories Inc Composições transdermais de ibuprofeno e seus métodos de utilização.
WO2013030789A1 (en) 2011-08-30 2013-03-07 Ranbaxy Laboratories Limited Pharmaceutical oral solid dosage form containing a poorly water soluble pde - iv inhibitor
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CN110403922A (zh) 2013-01-28 2019-11-05 理森制药股份公司 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法
MX2013001279A (es) * 2013-01-31 2013-08-26 Miguel Angel Garcia Perez Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
US20140275265A1 (en) * 2013-03-12 2014-09-18 Core Products International, Inc. Therapeutic cream for application to skin
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
JP2017529334A (ja) * 2014-08-27 2017-10-05 アッヴィ・インコーポレイテッド 局所製剤
PL3383363T3 (pl) 2015-11-30 2021-05-31 Anacor Pharmaceuticals, Inc. Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem
BR112018076114A2 (pt) * 2016-06-15 2019-03-26 Torrent Pharmaceuticals Limited composições tópicas de apremilast
US9895359B1 (en) * 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents

Also Published As

Publication number Publication date
EP4316590A2 (en) 2024-02-07
KR20200058402A (ko) 2020-05-27
IL273376B1 (en) 2024-03-01
US11534493B2 (en) 2022-12-27
JP7402301B2 (ja) 2023-12-20
JP2024028911A (ja) 2024-03-05
EP3684334A1 (en) 2020-07-29
KR102681877B1 (ko) 2024-07-04
CN119386013A (zh) 2025-02-07
JP2023027195A (ja) 2023-03-01
WO2019060379A1 (en) 2019-03-28
JP7664358B2 (ja) 2025-04-17
BR112020005421A2 (pt) 2020-09-29
EP3684334B1 (en) 2023-12-06
AU2018337752A1 (en) 2020-04-09
EA202090813A1 (ru) 2020-08-14
US20250312457A1 (en) 2025-10-09
IL273376A (en) 2020-05-31
BR112020005421A8 (pt) 2022-12-13
CN111107836A (zh) 2020-05-05
EP3684334C0 (en) 2023-12-06
EP4316590A3 (en) 2024-05-01
IL273376B2 (en) 2024-07-01
US20230091358A1 (en) 2023-03-23
MX2023011557A (es) 2023-10-09
ES2972843T3 (es) 2024-06-17
AU2018337752B2 (en) 2024-03-28
JP7191944B2 (ja) 2022-12-19
JP2020534303A (ja) 2020-11-26
CA3076002A1 (en) 2019-03-28
US20190091333A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2020003001A (es) Composiciones farmacéuticas de roflumilast en mezclas acuosas de solventes miscibles en agua, farmacéuticamente aceptables.
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
MX387723B (es) Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
UY38055A (es) Composiciones oftálmicas de compuestos de bencimidazol para uso unico diario
EA201892156A1 (ru) Система доставки
MX390495B (es) Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica.
AR034370A1 (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral
PE20160605A1 (es) Formulaciones de inhibidores de la syk
PE20200698A1 (es) Gel que comprende clorhexidina
CL2021000046A1 (es) Degradadores selectivos del receptor de estrógeno
AR091039A1 (es) Composiciones farmaceuticas topicas que comprenden terbinafina, uso y metodo de tratamiento
MX2019003105A (es) Composicion farmaceutica.
NO20053398L (no) Farmasoytiske preparater av sertaconazol for vaginal anvendelse.
PE20171246A1 (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos
MX390044B (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
CY1126071T1 (el) Φαρμακευτικα σκευασματα αναλογων κυκλοσπορινης
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
AR034854A1 (es) Compuesto de imidazol condensado, prodroga del mismo, composición farmaceutica y agente para reducir androgenos que lo contienen ,metodo para producirlo, sal diastereomerica de dicho compuesto y metodo para producir un compuesto opticamente activo del compuesto
AR085273A1 (es) Formulacion liquida libre de propelente que comprende una droga antimuscarinica
JOP20170197B1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول